Multifactorial Role of HIV-1 Vpr in Cell Apoptosis Revealed by a Naturally Truncated 54aa Variant

HIV-1 remains a global health challenge despite the success of antiretroviral therapy (ART), which suppresses viral replication but does not eliminate the virus. A key player in HIV-1’s ability to harm cells is the accessory protein viral protein R (Vpr), known for regulating apoptosis—programmed cell death. While previous research focused on Vpr’s C-terminal region (amino acids 52–96) as its main apoptosis-regulating domain, a 2021 study from Fudan University and collaborators uncovered new insights: a naturally truncated 54-amino acid Vpr variant (54Vpr) from AIDS patients and a novel N-terminal apoptosis domain in Vpr.

The Truncated Vpr Variant: A Surprising Find

Researchers analyzed Vpr from HIV-1 isolates, including a truncated variant (54Vpr) found in patients with advanced AIDS. They tested 54Vpr alongside full-length (wildtype) Vpr in two cell lines: 293T (a common lab cell line) and TZM-bl (a T-cell model for HIV infection).

Results were striking:

In 293T cells, neither wildtype nor 54Vpr caused significant cell death.
In TZM-bl cells, both variants significantly increased apoptosis compared to a control.

Crucially, 54Vpr worked just as well as full-length Vpr—suggesting the truncated form retains key apoptotic functions. Why the cell-type difference? The answer lies in adenine nucleotide translocator (ANT) proteins.

Vpr’s Apoptotic Effects Depend on ANT Isoforms

ANT proteins sit in mitochondria (cell “powerhouses”) and regulate energy flow. There are three main isoforms (ANT1, ANT2, ANT3), each with distinct roles. The study found:

TZM-bl cells have 100x higher ANT3 levels than 293T or HeLa cells. ANT3 is known to promote apoptosis.
293T cells have almost no ANT3—explaining why Vpr didn’t kill them.

When researchers added ANT1 or ANT3 to 293T cells alongside Vpr, apoptosis spiked. Adding ANT2 to TZM-bl cells reduced apoptosis. Co-immunoprecipitation (Co-IP) confirmed Vpr directly interacts with all three ANT isoforms—but the outcome (pro- or anti-apoptotic) depends on which ANT is present.

A New Death Domain in Vpr’s N-Terminus

The truncated 54Vpr (missing most of Vpr’s C-terminus) still induced apoptosis—hinting at a hidden domain in the N-terminus. To find it, the team created Vpr mutants truncated at different positions (23, 27, 30, 34, 38, 43 amino acids) and tested their ability to kill TZM-bl cells.

Key results:

Mutants truncated at 34, 38, or 43 amino acids (retaining the first “helix” of Vpr) caused apoptosis like wildtype Vpr.
Mutants truncated at 23, 27, or 30 amino acids (losing the first helix) failed to induce cell death.

The team confirmed the critical region: amino acids 23–37 in Vpr’s N-terminus. This domain worked as well as Vpr’s known C-terminal death domain (71–92 amino acids)—a major new discovery.

What This Means for HIV Research

Vpr is a “multitasker” that helps HIV replicate and evade the immune system. This study adds two key pieces to the puzzle:

Truncated Vpr variants from AIDS patients retain apoptotic activity, potentially contributing to immune cell loss in late-stage HIV.
ANT isoform levels dictate whether Vpr kills cells—explaining why Vpr affects some cell types (like T-cells) more than others.
The N-terminal death domain expands our understanding of Vpr’s structure and function, opening new targets for therapy.

While more research is needed to link these findings to human HIV infection, the study offers fresh clues about how Vpr drives cell death—and how the virus persists despite ART.

Original Study Citation

Du L, Wu CS, Sun J, Yu T, Lyu PP, Han SF, Qiu C, Meng ZF. Multifactorial role of HIV-Vpr in cell apoptosis revealed by a naturally truncated 54aa variant. Chinese Medical Journal. 2021;134(7):845–847. doi:10.1097/CM9.0000000000001297
Read the full study at doi.org/10.1097/CM9.0000000000001297

Was this helpful?

0 / 0